目的 探討咳喘寧膠囊聯(lián)合孟魯司特鈉和布地奈德治療兒童咳嗽變異性哮喘的臨床療效。方法 選取2015年1月-2016年1月在子長(zhǎng)縣人民醫(yī)院接受治療的兒童咳嗽變異性哮喘患兒86例，隨機(jī)分為對(duì)照組和治療組，每組各43例。對(duì)照組吸入布地奈德粉吸入劑，1 g/次，1次/8 h；且睡前口服孟魯司特鈉咀嚼片，年齡>5歲：5 mg/次，年齡≤5歲：4 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服咳喘寧膠囊，4粒/次，3次/d。兩組患兒均治療8周。觀察兩組的臨床療效，比較兩組咳嗽評(píng)分、肺功能和血清炎性因子的情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.40%、95.35%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組咳嗽評(píng)分顯著下降，而第一秒用力呼氣容積（FEV1）、用力肺活量（FVC）、最大呼氣流量（PEF）和FEV₁/FVC均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組免疫球蛋白E（IgE）、腫瘤壞死因子α（TNF-α）和白細(xì)胞介素-8（IL-8）水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 咳喘寧膠囊聯(lián)合孟魯司特鈉和布地奈德治療兒童咳嗽變異性哮喘具有較好的臨床療效，可改善臨床癥狀和肺功能，降低炎癥因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Kechuanning Capsules combined with montelukast sodium and budesonide in treatment of children with cough variant asthma. Methods Children (86 cases) with cough variant asthma in Zichang County People's Hospital from January 2015 to January 2016 were randomly divided into the control and treatment groups, and each group had 43 cases. Children in the control group were inhalation administered with Budesonide Powder for inhalation, 1 g/time, once every 8 h. Children in the control group were also po administered with Montelukast Sodium Chewable Tablets before bedtime, Age>5 years:5 mg/time, Age≤5 years:4 mg/time, once daily. Children in the treatment group were po administered with Kechuanning Capsules on the basis of the control group, 4 grains/time, three times daily. Children in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and cough scores, lung function, and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there was difference between two groups (P<0.05). After treatment, the cough scores in two groups were significantly decreased, but FEV1, FVC, PEF, and FEV₁/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, IgE, TNF-α, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kechuanning Capsules combined with montelukast sodium and budesonide has clinical curative effect in treatment of children with cough variant asthma, and can improve clinical symptoms and lung function, reduce the level of inflammatory factors, which has a certain clinical application value.